Research by Dr. Gritsman shows that crizotinib, a drug approved for treating lung cancer, is also effective in people with a type of blood cancer called myeloproliferative neoplasms (MPNs). The grant will help her laboratory determine if the drug also prevents out-of-control blood cell division in mouse models of MPN, with the goal of moving the drug swiftly into clinical trials.
The ACS also has awarded a $300,000 grant to Brendon M. Stiles, MD, and Vikas Mehta, MD, MPH, FACS, for the Building Reliable Oncology Navigation, Centered Around Neoadjuvant Therapy (BRONx-CAN) Project. Dr. Stiles is Professor, Cardiothoracic & Vascular Surgery, Oncology and Medicine; Chief, Thoracic Surgery and Surgical Oncology, Montefiore Einstein; and Associate Director for Surgical Services, MECC. Dr. Mehta is Vice Chair and Associate Professor, Otolaryngology-Head and Neck Surgery, Montefiore Einstein, and Director, Quality Improvement, MECC. BRONx-CAN is an innovative patient navigation program to coordinate patients with locally advanced, nonmetastatic lung cancer and certain gastrointestinal cancers, such as esophageal, gastric, pancreatic and rectal cancers, who are undergoing neoadjuvant therapy (NAT).